aTyr seeks to develop innovative therapeutics to address the unmet needs of patients by developing a novel class of biologic drugs. We have developed proprietary methods for discovering Physiocrines„¢, extracellular proteins that are derived from the tRNA synthetase family of enzymes, and which were predominantly overlooked by other genomic and secretome discovery efforts. aTyr™s proprietary discovery approach and expertise has enabled the exploration of this completely new class of biologic targets, and has allowed aTyr to establish a unique and comprehensive intellectual property portfolio across the Physiocrine family. We are currently developing a portfolio of Physiocrine therapeutic proteins, and focusing on indications in the areas of hematology, immune modulation, infection, and metabolism.
Silicon Valley Bank||undisclosed|
Deerfield Management Company, L.P.|
Federated Kaufmann Funds
Rock Springs Capital
Sphera Global Healthcare
T. Rowe Price Associates